You're been inactive for a while. For security reason, we'll automatically sign you out from our website. Please Click "Login" to extend your session
Access your patient history, lab results, future appointments and more.
Login via mobile number is currently unavailable. Our apologies for the inconvenience.
New to Bumrungrad? Create Account
Explore the latest news and easily book appointments with our world-class doctors.
Already have an account? Log In
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy Evaluating patients with possible 5-alpha reductase deficiency
The principal prostatic androgen is dihydrotestosterone (DHT). Levels of DHT remain normal with aging, despite a decrease in the plasma testosterone, and are not elevated in benign prostatic hyperplasia (BPH).
DHT is generated by reduction of testosterone by 5-alpha reductase. Two isoenzymes of 5-alpha reductase have been discovered. Type 1 is present in most tissues in the body where 5-alpha reductase is expressed, and is the dominant form in sebaceous glands. Type 2 is the dominant isoenzyme in genital tissues, including the prostate.